<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02103764</url>
  </required_header>
  <id_info>
    <org_study_id>DSG-SIAUB</org_study_id>
    <nct_id>NCT02103764</nct_id>
  </id_info>
  <brief_title>Efficacy of Cyclic DSG Compared With Cyclic MPA for the Treatment of Anovulatory DUB</brief_title>
  <acronym>SI-AUB-RCT</acronym>
  <official_title>The Effectiveness of Cyclic Desogestrel Therapy for Abnormal Uterine Bleeding Associated With Anovulation: a Non-inferiority Double Blinded Randomized Control Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of the present study is to determine the effectiveness of cyclic desogestrel&#xD;
      (DSG) compared with cyclic medroxyprogesterone acetate for the treatment of anovulatory&#xD;
      dysfunctional uterine bleeding (DUB) in the following aspects:&#xD;
&#xD;
        1. Endometrial histopathology changes&#xD;
&#xD;
        2. Menstrual cycle control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Anovulatory dysfunctional uterine bleeding (DUB) is the most common cause of abnormal uterine&#xD;
      bleeding especially in postmenarcheal adolescent, perimenopausal women, patient with&#xD;
      polycystic ovary syndrome (PCOS) and in obese women. Aims of treatment in women with&#xD;
      anovulatory DUB are to restore the natural control mechanism of endometrium (introduce normal&#xD;
      synchronous growth, development, shedding of a structural stable endometrium) and to prevent&#xD;
      endometrial hyperplasia. The two main treatment options are estrogen-progestin therapy and&#xD;
      progestin therapy. Women who are sexually active and not immediately prepared to pursue&#xD;
      pregnancy are best manage by estrogen-progestin treatment especially combined oral&#xD;
      contraceptive pills (COCs) but in perimenopausal women, obese women or women who can't&#xD;
      tolerate COCs or have contraindications in using COCs, cyclic progestin will be the treatment&#xD;
      of choice. Common used progestin in anovulatory DUB is medroxyprogesterone acetate (MPA) 5-10&#xD;
      mg/day for 10-14 days each month. This progestin has strong progestogenic effect but has some&#xD;
      undesirable effect such as glucocorticoid effect, mineralocorticoid effect and androgenic&#xD;
      effect. Long term using this progestin especially in obese women or perimenopausal women who&#xD;
      have risk for diabetes mellitus and dyslipidemia may be negative effect to glucose and lipid&#xD;
      metabolism. DSG is the third generation progestin with no glucocorticoid, mineralocorticoid&#xD;
      effect and low androgenic effect may be the better choice of treatment but the data of DSG in&#xD;
      treatment of anovulatory DUB us scanty. So this study will evaluate the effect of cyclic DSG&#xD;
      in endometrial histology changing and lipid, glucose metabolism in patient with anovulatory&#xD;
      DUB.&#xD;
&#xD;
      Comparison : Women with anovulatory DUB are randomized into two groups, receiving a course of&#xD;
      either cyclic DSG or cyclic MPA. The main outcome measured is to compare the effect of both&#xD;
      interventions on endometrial histology changing.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date type="Actual">August 2013</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Actual">July 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The change in endometrial histology</measure>
    <time_frame>Baseline, Day 8 or 9 or 10 of treatment period in first month</time_frame>
    <description>The participants are evaluated for changing of endometrial histology at day 8 or 9 or 10 of treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The occurrence of withdrawal bleeding</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the occurrence of withdrawal bleeding between cyclic DSG and cyclic MPA groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of cyclic DSG on lipid metabolism compared with cyclic MPA</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the change of total cholesterol (TC), triglyceride, HDL-C, and LDL-C between cyclic DSG and cyclic MPA groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of cyclic DSG on glucose metabolism compared with cyclic MPA</measure>
    <time_frame>6 months</time_frame>
    <description>To compare the change of fasting blood glucose, and fasting insulin between cyclic DSG and cyclic MPA groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>At day 8 or 9 or 10 of the first cycle and 3, 6 month</time_frame>
    <description>To compare the adverse events, including side effects between cyclic DSG and cyclic MPA groups.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Dysfunctional Uterine Bleeding</condition>
  <arm_group>
    <arm_group_label>Desogestrel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Desogestrel</intervention_name>
    <description>Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month</description>
    <arm_group_label>Desogestrel</arm_group_label>
    <other_name>Cerazette</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Medroxyprogesterone acetate</intervention_name>
    <description>Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month</description>
    <arm_group_label>Medroxyprogesterone acetate</arm_group_label>
    <other_name>Provera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Premenopausal women with anovular DUB (proved by endometrial histology)&#xD;
&#xD;
          -  Age &gt; 18 yr.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any uterine pathology that might cause abnormal uterine bleeding&#xD;
&#xD;
          -  Contraindication to progestin treatment (such as breast cancer)&#xD;
&#xD;
          -  Severe drug allergy towards a progestogen&#xD;
&#xD;
          -  Intake of any hormonal treatment in the previous 3 months&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Manee Rattanachaiyanont, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Faculty of Medicine Siriraj Hospital, Mahidol University</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 18, 2014</study_first_submitted>
  <study_first_submitted_qc>April 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2014</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mahidol University</investigator_affiliation>
    <investigator_full_name>Manee Rattanachaiyanont</investigator_full_name>
    <investigator_title>Department of Obstetrics and Gynecology, Faculty of Medicine Siriraj Hospital</investigator_title>
  </responsible_party>
  <keyword>Anovulatory Dysfunctional Uterine Bleeding</keyword>
  <keyword>cyclic desogestrel</keyword>
  <keyword>cyclic medroxyprogesterone acetate</keyword>
  <keyword>lipid metabolism</keyword>
  <keyword>glucose metabolism</keyword>
  <keyword>endometrial histology changing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Hemorrhage</mesh_term>
    <mesh_term>Metrorrhagia</mesh_term>
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Medroxyprogesterone Acetate</mesh_term>
    <mesh_term>Medroxyprogesterone</mesh_term>
    <mesh_term>Desogestrel</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>September 17, 2019</submitted>
    <returned>October 9, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

